Adaptimmune Therapeutics plc (ADAPY)
| Market Cap | 8.48M -84.0% |
| Revenue (ttm) | 5.92M -96.6% |
| Net Income | 25.21M |
| EPS | 0.08 |
| Shares Out | 265.05M |
| PE Ratio | 0.41 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,723 |
| Open | 0.0275 |
| Previous Close | 0.0325 |
| Day's Range | 0.0275 - 0.0325 |
| 52-Week Range | 0.0001 - 0.0926 |
| Beta | 0.75 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom. [Read more]
Financial Performance
Financial StatementsNews
Adaptimmune Announces Changes to Board and Executive Leadership Team
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to...
Adaptimmune Announces Delisting from Nasdaq
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Compa...
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to ...
Adaptimmune Therapeutics Quarterly report: Q2 2025
Adaptimmune Therapeutics has published its Q2 2025 quarterly earnings report on August 13, 2025.
Adaptimmune Therapeutics Earnings release: Q2 2025
Adaptimmune Therapeutics released its Q2 2025 earnings on August 13, 2025, summarizing the period's financial results.
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase ...
Adaptimmune Therapeutics Earnings Call Transcript: Q1 2025
TECELRA's launch exceeded expectations with $4M Q1 sales and strong patient uptake, supporting $35M–$45M full-year guidance. Gross margin was 78%, and all apheresed patients have been infused. Strategic review and cost controls continue amid less than 12 months of cash runway.
Adaptimmune Therapeutics Quarterly report: Q1 2025
Adaptimmune Therapeutics has published its Q1 2025 quarterly earnings report on May 13, 2025.
Adaptimmune Therapeutics Earnings release: Q1 2025
Adaptimmune Therapeutics released its Q1 2025 earnings on May 13, 2025, summarizing the period's financial results.
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45...
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...
Adaptimmune Therapeutics Proxy statement: Proxy Filing
Adaptimmune Therapeutics filed a proxy statement on April 25, 2025, providing details for shareholder voting and corporate governance matters.
Adaptimmune Therapeutics Registration statement: Registration Filing
Adaptimmune Therapeutics filed a registration statement on April 18, 2025, providing details about a securities offering with the SEC.
Adaptimmune Therapeutics Proxy statement: Proxy Filing
Adaptimmune Therapeutics filed a proxy statement on April 15, 2025, providing details for shareholder voting and corporate governance matters.
Adaptimmune Therapeutics Earnings Call Transcript: Q4 2024
TECELRA's launch is ahead of schedule, with strong early revenue, robust manufacturing, and high reimbursement rates. The company expects accelerating sales, a 2025 revenue target of $25M, and aims for profitability in 2027, but will require additional financing to reach that goal.
Adaptimmune Therapeutics Annual report: Q4 2024
Adaptimmune Therapeutics has published its Q4 2024 annual report on March 20, 2025.
Adaptimmune Therapeutics Earnings release: Q4 2024
Adaptimmune Therapeutics released its Q4 2024 earnings on March 20, 2025, summarizing the period's financial results.
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submiss...
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with c...
Adaptimmune Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
The session highlighted strong early commercial uptake for Tecelra, the first approved engineered T-cell therapy for synovial sarcoma, and detailed plans for expanding reach with lete-cel and a robust pipeline. High market penetration is expected due to lack of alternatives, with steady growth projected over the next 2–3 years.
Adaptimmune Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference
TECELRA, the first TCR T-cell therapy for solid tumors, is transforming synovial sarcoma treatment with strong early demand and durable responses. Commercial rollout is ahead of schedule, with expanded site activation and robust insurance coverage. Lete-cel is on track for regulatory submission, targeting further market growth.
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor can...
Adaptimmune Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
First-in-class engineered T-cell therapy for solid tumors launched, with Tecelra approved for synovial sarcoma and lete-cel advancing toward approval. Commercial infrastructure and payer coverage are robust, with a pipeline targeting broader indications and global expansion opportunities.
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be fe...
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from...